### Section: Immunomodulators and antineoplastics

#### 8.2. Antineoplastics and supportive medicines

#### 8.2.1. Cytotoxic medicines

**Dacarbazine**

**Indication**
- Hodgkin lymphoma

**INN**
- Dacarbazine

**Medicine type**
- Chemical agent

**List type**
- Complementary

**Formulations**
- Parenteral > General injections > IV: 100 mg in vial powder for injection

**ATC codes:**
- L01AX04
- EMLc

**ICD11 code:**
- 2C10.Z

**INN**
- Dacarbazine

**Medicine type**
- Chemical agent

**List type**
- Complementary

**Formulations**
- Parenteral > General injections > IV: 100 mg in vial powder for injection

**EML status history**
- First added in 1989 (TRS 796)
- Changed in 2002 (TRS 914)
- Changed in 2007 (TRS 950)
- Changed in 2011 (TRS 965)
- Changed in 2015 (TRS 994)

**Sex**
- All

**Age**
- Also recommended for children

**Therapeutic alternatives**
- The recommendation is for this specific medicine

**Patent information**
- Patents have expired in most jurisdictions
  - Read more about patents.

**Tags**
- Cancer

**Wikipedia**
- Dacarbazine

**DrugBank**
- Dacarbazine

---

**Summary of evidence and Expert Committee recommendations**

In 2015, as part of the comprehensive review of cancer medicines undertaken by the Expert Committee, listing for dacarbazine on the complementary list of the EML for use in treatment protocols for Hodgkin lymphoma was specifically endorsed and it was added to the complementary list of the EMLc for this indication. The relevant extracts from TRS994 regarding the Expert Committee's 2015 consideration of treatment protocols for Hodgkin lymphoma in adults and in paediatrics are attached.